Viatris Inc. (VTRS)
USD 8.65
(2.13%)
USD 8.65
(2.13%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 766.2 Million USD | -52.55% |
| 2022 | 1.61 Billion USD | 4849.71% |
| 2021 | -34 Million USD | 83.87% |
| 2020 | -210.8 Million USD | -129.46% |
| 2019 | 715.5 Million USD | -20.99% |
| 2018 | 905.6 Million USD | -36.99% |
| 2017 | 1.43 Billion USD | 105.55% |
| 2016 | 699.2 Million USD | -52.14% |
| 2015 | 1.46 Billion USD | 8.01% |
| 2014 | 1.35 Billion USD | 19.12% |
| 2013 | 1.13 Billion USD | -17.42% |
| 2012 | 1.37 Billion USD | 21.38% |
| 2011 | 1.13 Billion USD | 31.01% |
| 2010 | 864.64 Million USD | 12.53% |
| 2009 | 768.36 Million USD | 9.84% |
| 2008 | 699.51 Million USD | 88.19% |
| 2007 | 371.71 Million USD | 0.0% |
| 2006 | 287.38 Million USD | -4.89% |
| 2005 | 320.72 Million USD | 7.24% |
| 2004 | 299.08 Million USD | -34.99% |
| 2003 | 460.04 Million USD | 0.0% |
| 2002 | 395.17 Million USD | 1918.49% |
| 2001 | 19.57 Million USD | -91.22% |
| 2000 | 222.95 Million USD | 12.89% |
| 1999 | 197.5 Million USD | 102.98% |
| 1998 | 97.3 Million USD | 67.76% |
| 1997 | 58 Million USD | -42.12% |
| 1996 | 100.2 Million USD | -27.34% |
| 1995 | 137.9 Million USD | 148.92% |
| 1994 | 55.4 Million USD | -23.48% |
| 1993 | 72.4 Million USD | 175.29% |
| 1992 | 26.3 Million USD | 42.16% |
| 1991 | 18.5 Million USD | -8.42% |
| 1990 | 20.2 Million USD | -4.72% |
| 1989 | 21.2 Million USD | -42.55% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 203.9 Million USD | 144.86% |
| 2024 Q2 | -239.9 Million USD | -217.66% |
| 2023 Q2 | 369.2 Million USD | -7.65% |
| 2023 Q3 | 451.7 Million USD | 22.35% |
| 2023 Q4 | -454.5 Million USD | -200.62% |
| 2023 Q1 | 399.8 Million USD | 298.61% |
| 2023 FY | 2.05 Billion USD | 390.23% |
| 2022 Q4 | -201.3 Million USD | -135.94% |
| 2022 FY | 418.8 Million USD | 109.96% |
| 2022 Q3 | 560.1 Million USD | 2.08% |
| 2022 Q2 | 548.7 Million USD | -22.43% |
| 2022 Q1 | 707.4 Million USD | 1011.6% |
| 2021 Q4 | -77.6 Million USD | -121.7% |
| 2021 Q2 | -47.8 Million USD | 82.04% |
| 2021 Q3 | 357.6 Million USD | 848.12% |
| 2021 FY | -4.2 Billion USD | -3608.55% |
| 2021 Q1 | -266.2 Million USD | 69.79% |
| 2020 Q4 | -881.1 Million USD | -350.74% |
| 2020 Q1 | 184.7 Million USD | -32.17% |
| 2020 Q2 | 134.19 Million USD | -27.34% |
| 2020 Q3 | 351.4 Million USD | 161.85% |
| 2020 FY | -113.4 Million USD | 91.72% |
| 2019 FY | -1.36 Billion USD | -251.17% |
| 2019 Q3 | 323.7 Million USD | 238.95% |
| 2019 Q4 | 272.3 Million USD | -15.88% |
| 2019 Q1 | 24 Million USD | -89.69% |
| 2019 Q2 | 95.5 Million USD | 297.92% |
| 2018 Q4 | 232.8 Million USD | -31.16% |
| 2018 Q1 | 155.7 Million USD | -62.86% |
| 2018 FY | 905.6 Million USD | -36.98% |
| 2018 Q2 | 178.9 Million USD | 14.9% |
| 2018 Q3 | 338.2 Million USD | 89.04% |
| 2017 Q2 | 473.8 Million USD | 108.08% |
| 2017 Q1 | 227.7 Million USD | -27.9% |
| 2017 FY | 1.43 Billion USD | 104.83% |
| 2017 Q3 | 316.5 Million USD | -33.2% |
| 2017 Q4 | 419.2 Million USD | 32.45% |
| 2016 Q2 | 410.9 Million USD | 289.11% |
| 2016 Q3 | -130.69 Million USD | -131.81% |
| 2016 Q4 | 315.8 Million USD | 341.62% |
| 2016 FY | 701.6 Million USD | -51.97% |
| 2016 Q1 | 105.6 Million USD | -75.09% |
| 2015 Q3 | 601.1 Million USD | 117.32% |
| 2015 Q1 | 159.3 Million USD | -59.41% |
| 2015 FY | 1.46 Billion USD | 8.01% |
| 2015 Q4 | 423.9 Million USD | -29.48% |
| 2015 Q2 | 276.6 Million USD | 73.63% |
| 2014 Q3 | 495 Million USD | 118.93% |
| 2014 Q2 | 226.1 Million USD | -5.4% |
| 2014 Q1 | 239 Million USD | -12.52% |
| 2014 Q4 | 392.5 Million USD | -20.71% |
| 2014 FY | 1.35 Billion USD | 19.12% |
| 2013 Q3 | 339.8 Million USD | 0.0% |
| 2013 Q1 | 213.84 Million USD | -18.58% |
| 2013 Q4 | 273.2 Million USD | -19.6% |
| 2013 FY | 1.13 Billion USD | 2.36% |
| 2013 Q2 | 308.61 Million USD | 44.32% |
| 2012 FY | 1.1 Billion USD | 10.33% |
| 2012 Q4 | 262.65 Million USD | -20.39% |
| 2012 Q3 | 329.91 Million USD | 27.97% |
| 2012 Q2 | 257.8 Million USD | 4.64% |
| 2012 Q1 | 246.37 Million USD | -0.41% |
| 2011 Q1 | 211.67 Million USD | 124.77% |
| 2011 FY | 1 Billion USD | 39.34% |
| 2011 Q2 | 280.47 Million USD | 32.5% |
| 2011 Q4 | 247.39 Million USD | -6.96% |
| 2011 Q3 | 265.9 Million USD | -5.19% |
| 2010 Q4 | 94.17 Million USD | -59.81% |
| 2010 Q1 | 198.5 Million USD | 230.73% |
| 2010 Q2 | 194.58 Million USD | -1.98% |
| 2010 Q3 | 234.31 Million USD | 20.42% |
| 2010 FY | 721.58 Million USD | 37.88% |
| 2009 Q3 | 61.27 Million USD | -64.93% |
| 2009 Q4 | 60.02 Million USD | -2.05% |
| 2009 Q1 | 227.34 Million USD | 557.23% |
| 2009 FY | 523.35 Million USD | 75.69% |
| 2009 Q2 | 174.71 Million USD | -23.15% |
| 2008 Q4 | 34.59 Million USD | -93.83% |
| 2008 Q3 | 560.83 Million USD | 657.88% |
| 2008 Q1 | -371.53 Million USD | 0.0% |
| 2008 Q2 | 74 Million USD | 119.92% |
| 2008 FY | 297.88 Million USD | -30.33% |
| 2007 Q3 | 91.89 Million USD | -51.14% |
| 2007 Q4 | - USD | -100.0% |
| 2007 FY | 427.55 Million USD | 48.77% |
| 2007 Q1 | -7.79 Million USD | -104.24% |
| 2007 Q2 | 188.07 Million USD | 2513.37% |
| 2006 Q2 | 117.14 Million USD | 27.61% |
| 2006 FY | 287.38 Million USD | -4.89% |
| 2006 Q1 | 91.8 Million USD | 17.64% |
| 2006 Q3 | 134.54 Million USD | 14.85% |
| 2006 Q4 | 183.65 Million USD | 36.5% |
| 2005 Q2 | 59.56 Million USD | 12.03% |
| 2005 Q1 | 53.16 Million USD | 8.55% |
| 2005 FY | 302.17 Million USD | -38.93% |
| 2005 Q4 | 78.03 Million USD | 34.59% |
| 2005 Q3 | 57.98 Million USD | -2.66% |
| 2004 Q2 | 126.49 Million USD | 16.89% |
| 2004 Q3 | 73.52 Million USD | -41.88% |
| 2004 Q4 | 48.98 Million USD | -33.38% |
| 2004 FY | 494.8 Million USD | 19.52% |
| 2004 Q1 | 108.22 Million USD | -13.76% |
| 2003 Q2 | 126.91 Million USD | 13.67% |
| 2003 Q1 | 111.64 Million USD | 8.72% |
| 2003 Q4 | 125.48 Million USD | -6.47% |
| 2003 FY | 413.98 Million USD | 4.76% |
| 2003 Q3 | 134.17 Million USD | 5.72% |
| 2002 FY | 395.17 Million USD | 1918.49% |
| 2002 Q4 | 102.69 Million USD | -2.19% |
| 2002 Q3 | 104.99 Million USD | 10.93% |
| 2002 Q2 | 94.65 Million USD | -15.23% |
| 2002 Q1 | 111.65 Million USD | -6.91% |
| 2001 Q4 | 119.94 Million USD | 20.87% |
| 2001 Q2 | 64.33 Million USD | 172.03% |
| 2001 Q1 | -89.32 Million USD | -283.52% |
| 2001 FY | 19.57 Million USD | -91.22% |
| 2001 Q3 | 99.23 Million USD | 54.24% |
| 2000 Q1 | 57.85 Million USD | -0.93% |
| 2000 Q4 | 48.67 Million USD | 19.09% |
| 2000 Q3 | 40.87 Million USD | 111.14% |
| 2000 Q2 | 19.35 Million USD | -66.54% |
| 2000 FY | 222.95 Million USD | 12.89% |
| 1999 FY | 197.5 Million USD | 102.98% |
| 1999 Q1 | 49.7 Million USD | -3.31% |
| 1999 Q2 | 46.4 Million USD | -6.64% |
| 1999 Q3 | 60.4 Million USD | 30.17% |
| 1999 Q4 | 58.4 Million USD | -3.31% |
| 1998 Q2 | 46 Million USD | 178.79% |
| 1998 FY | 97.3 Million USD | 67.76% |
| 1998 Q3 | 50.3 Million USD | 9.35% |
| 1998 Q4 | 51.4 Million USD | 2.19% |
| 1998 Q1 | 16.5 Million USD | -34.78% |
| 1997 Q1 | 14.7 Million USD | -13.53% |
| 1997 FY | 58 Million USD | -42.12% |
| 1997 Q4 | 25.3 Million USD | -35.46% |
| 1997 Q3 | 39.2 Million USD | 139.02% |
| 1997 Q2 | 16.4 Million USD | 11.56% |
| 1996 FY | 100.2 Million USD | -27.34% |
| 1996 Q2 | 10.9 Million USD | -29.22% |
| 1996 Q4 | 17 Million USD | 9.68% |
| 1996 Q3 | 15.5 Million USD | 42.2% |
| 1996 Q1 | 15.4 Million USD | -17.2% |
| 1995 Q1 | 37.9 Million USD | 9.22% |
| 1995 FY | 137.9 Million USD | 148.92% |
| 1995 Q2 | 36.4 Million USD | -3.96% |
| 1995 Q4 | 18.6 Million USD | -37.37% |
| 1995 Q3 | 29.7 Million USD | -18.41% |
| 1994 Q4 | 34.7 Million USD | 2.06% |
| 1994 Q1 | 16.5 Million USD | 14.58% |
| 1994 Q3 | 34 Million USD | 8.28% |
| 1994 Q2 | 31.4 Million USD | 90.3% |
| 1994 FY | 55.4 Million USD | -23.48% |
| 1993 Q3 | 10.3 Million USD | -26.95% |
| 1993 Q4 | 14.4 Million USD | 39.81% |
| 1993 FY | 72.4 Million USD | 175.29% |
| 1993 Q1 | 23.3 Million USD | 5.43% |
| 1993 Q2 | 14.1 Million USD | -39.48% |
| 1992 Q3 | 17.5 Million USD | 88.17% |
| 1992 Q1 | 10.2 Million USD | 70.0% |
| 1992 FY | 26.3 Million USD | 42.16% |
| 1992 Q2 | 9.3 Million USD | -8.82% |
| 1992 Q4 | 22.1 Million USD | 26.29% |
| 1991 Q3 | 5.2 Million USD | 10.64% |
| 1991 Q1 | 5.2 Million USD | 18.18% |
| 1991 Q4 | 6 Million USD | 15.38% |
| 1991 FY | 18.5 Million USD | -8.42% |
| 1991 Q2 | 4.7 Million USD | -9.62% |
| 1990 Q2 | 5.2 Million USD | -28.77% |
| 1990 FY | 20.2 Million USD | -4.72% |
| 1990 Q4 | 4.4 Million USD | 18.92% |
| 1990 Q1 | 7.3 Million USD | 40.38% |
| 1990 Q3 | 3.7 Million USD | -28.85% |
| 1989 Q2 | 3.8 Million USD | 108.41% |
| 1989 FY | 21.2 Million USD | -42.55% |
| 1989 Q1 | -45.2 Million USD | -303.6% |
| 1989 Q4 | 5.2 Million USD | 30.0% |
| 1989 Q3 | 4 Million USD | 5.26% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -1531.219% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 5173.5% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | -358.91% |
| Cosmos Health Inc. | -21.83 Million USD | 3609.653% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 3921.436% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 592.534% |
| Cronos Group Inc. | -81.37 Million USD | 1041.562% |
| Incannex Healthcare Limited | -30.04 Million USD | 2650.514% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 2056.938% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -8111.339% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 16275.73% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 16111.539% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 16111.539% |
| SCYNEXIS, Inc. | 72.66 Million USD | -954.37% |
| Safety Shot Inc | -12.18 Million USD | 6388.497% |
| Theratechnologies Inc. | -10.62 Million USD | 7309.937% |
| Alpha Teknova, Inc. | -35.56 Million USD | 2254.486% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 21825.237% |
| Pacira BioSciences, Inc. | 87.67 Million USD | -773.909% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 16398.66% |
| Dynavax Technologies Corporation | -37.02 Million USD | 2169.245% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | -266.54% |
| Radius Health, Inc. | -3.92 Million USD | 19621.019% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 30562.58% |
| Alvotech | -354.86 Million USD | 315.916% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 580.735% |
| SIGA Technologies, Inc. | 83.62 Million USD | -816.275% |
| Shineco, Inc. | -17.06 Million USD | 4589.662% |
| Silver Spike Investment Corp. | 7.34 Million USD | -10338.536% |
| Journey Medical Corporation | -2.07 Million USD | 37060.926% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 5726.64% |
| Embecta Corp. | 221.5 Million USD | -245.914% |
| Harrow Health, Inc. | 580 Thousand USD | -132003.448% |
| Procaps Group, S.A. | 38.97 Million USD | -1865.976% |
| Biofrontera Inc. | -22.67 Million USD | 3478.754% |
| DURECT Corporation | -36.88 Million USD | 2177.324% |
| PainReform Ltd. | -9.58 Million USD | 8094.574% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 14641.659% |
| OptiNose, Inc. | -22.74 Million USD | 3468.208% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -5965.548% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -6017.365% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 12436.537% |
| ProPhase Labs, Inc. | -21.61 Million USD | 3645.089% |
| Phibro Animal Health Corporation | 53.31 Million USD | -1337.119% |
| Procaps Group S.A. | 52.32 Million USD | -1364.338% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 9089.792% |
| Rockwell Medical, Inc. | -6.67 Million USD | 11587.256% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 14683.175% |
| Tilray Brands, Inc. | -174.74 Million USD | 538.467% |
| PetIQ, Inc. | 60.01 Million USD | -1176.681% |
| Talphera, Inc. | -16.88 Million USD | 4636.681% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -205.381% |
| Alimera Sciences, Inc. | -1.47 Million USD | 52187.016% |
| Assertio Holdings, Inc. | -243.53 Million USD | 414.615% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 13103.235% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 655.826% |
| Hempacco Co., Inc. | -8.81 Million USD | 8794.685% |
| Alvotech | -354.86 Million USD | 315.916% |
| Lantheus Holdings, Inc. | 364.64 Million USD | -110.124% |
| Kamada Ltd. | 10.06 Million USD | -7513.275% |
| Currenc Group, Inc. | -6.64 Million USD | 11629.112% |
| Indivior PLC | -4 Million USD | 19255.0% |
| Evoke Pharma, Inc. | -7.43 Million USD | 10411.011% |
| Flora Growth Corp. | -50.35 Million USD | 1621.627% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 3921.436% |
| Evolus, Inc. | -49.23 Million USD | 1656.273% |
| HUTCHMED (China) Limited | 18.37 Million USD | -4069.796% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | -288.96% |
| Akanda Corp. | -10.05 Million USD | 7722.839% |